Skip to main content

CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC).

Publication ,  Conference
Rosenberg, JE; Halabi, S; Sanford, BL; Himelstein, AL; Atkins, JN; Hohl, R; Seagren, SL; Bajorin, DF; Small, EJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 20, 2006

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

June 20, 2006

Volume

24

Issue

18

Start / End Page

237S / 237S

Location

Atlanta, GA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rosenberg, J. E., Halabi, S., Sanford, B. L., Himelstein, A. L., Atkins, J. N., Hohl, R., … Small, E. J. (2006). CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 24, pp. 237S-237S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY.
Rosenberg, J. E., S. Halabi, B. L. Sanford, A. L. Himelstein, J. N. Atkins, R. Hohl, S. L. Seagren, D. F. Bajorin, and E. J. Small. “CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC).” In JOURNAL OF CLINICAL ONCOLOGY, 24:237S-237S. AMER SOC CLINICAL ONCOLOGY, 2006.
Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl R, et al. CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 237S-237S.
Rosenberg, J. E., et al. “CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC).JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. 18, AMER SOC CLINICAL ONCOLOGY, 2006, pp. 237S-237S.
Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl R, Seagren SL, Bajorin DF, Small EJ. CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 237S-237S.

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

June 20, 2006

Volume

24

Issue

18

Start / End Page

237S / 237S

Location

Atlanta, GA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences